Phase I and Phase II clinical trials to develop PH46A as a novel, first-in-class, small molecule therapeutic to transform the therapy of ulcerative colitis.

A new anti-inflammatory drug, PH46A, is entering clinical trials for ulcerative colitis, a chronic gut disease that causes debilitating bloody diarrhoea. The problem is that most existing treatments are designed for severe cases, leaving the majority of patients with mild-to-moderate disease without a drug developed specifically for them. PH46A is a small molecule, not a biologic, which means it could be cheaper to manufacture and easier to administer. In animal models, it has matched the effectiveness of steroids without their toxic side effects. If the trials succeed, PH46A could become the first new chemical entity in decades for mild-to-moderate ulcerative colitis. This would give millions of patients—often young adults in their most productive years—a treatment that controls symptoms without the burden of frequent hospital visits or severe side effects. For health services, it could reduce the costs of managing a relapsing condition that currently causes high rates of work absenteeism and emergency care. The project is a straightforward drug development programme, not fundamental science, with a clear target: transforming everyday management of a common, disruptive disease.